
Rinri Therapeutics have announced the MHRA has awarded an innovation passport to the company’s lead candidate, Rincell-1. Rincell-1 is a …

A record three million people received vital NHS cancer tests from March 2021 to February 2022, compared to 2.4 million …

According to health experts, many COVID-19 patients are still suffering the effects of the condition months after they first started …

The US FDA has approved the first in vitro diagnostic to aid in the early detection of Alzheimer’s disease (AD). …
The China National Medical Products Administration (NMPA) has granted conditional approval of BLINCYTO (blinatumomab), as an injection for the treatment …
Amphista and Bristol-Myers Squibb have announced a strategic collaboration and license agreement.Under the terms of the collaboration, BMS and Amphista …

Researchers at the University of California San Diego have developed a smartphone app with the potential to screen for Alzheimer’s …

A rapid communication released by WHO Global Tuberculosis Programme has announced upcoming updates to the guidance on the treatment of …

Galapagos Biotech LTD has announced that further to approval from the Health Service Executive (HSE), eligible patients in Ireland will …

The EC has announced plans to make health data easier to access for patients, medics, regulators, and researchers, to improve …

The FDA has expanded the indication of Supernus’s Qelbree to patients aged 18 and older, marking the drug as the …

The EC has approved the use of Cabotemyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally …

The High Court has ruled that government policies on discharging untested patients from hospital to care homes in England, at …

Pfizer has announced that it will open the first ever US sites in its Phase III trial study, evaluating its …

Bristol Myers Squibb has received approval from the FDA for their drug, Camzyosâ„¢ (mavacamten), marking the drug as the first …

OMass Therapeutics have announced the $100 million (£75.5 million) Series B financing to progress its drug pipeline in immunology and …

NOCIRA is the first company to announce the FDA’s Breakthrough Device designation for the treatment of migraine attacks in both …

Quell Therapeutics and Cellistic have entered into a strategic collaboration for the co-development of an iPSC-derived Treg cell therapy platform. …

Around 190 unexplained cases of severe hepatitis have been found in children around the world, as scientists urgently investigate what …

Orexo has announced that their partner, Gesynta Pharma has been granted Orphan Drug Designation by the FDA, for OX-MPI (GS248), …